The effect of famotidine on gastroesophageal and duodeno-gastro-esophageal refluxes in critically ill Patients

Ying Xin, Ning Dai, Lan Zhao, Jian-Guo Wang, Jian-Ming Si

Ying Xin, Ning Dai, Lan Zhao, Jian-Guo Wang, Department of Gastroenterology, Sir Run Run Shaw Hospital, Hangzhou 310016, Zhejiang Province, China
Jian-Ming Si, Zhejiang University, medical college, Hangzhou 310031, Zhejiang Province, China
Correspondence: Dr. Ying Xin, Department of Gastroenterology, Sir Run Run Shaw Hospital, Hangzhou 310016, Zhejiang Province, China. xinying20012001@yahoo.com.cn
Telephone: +86-571-86994122
Received: 2002-06-14 Accepted: 2002-07-25

Abstract

AIM: To investigate the effect of famotidine on gastroesophageal reflux (GER) and duodeno-gastro-esophageal reflux (DGER) and to explore its possible mechanisms. To identify the relevant factors of the reflux.

METHODS: Nineteen critically ill patients were consecutively enrolled in the study. Dynamic 24 hours monitoring of GER and DGER before and after administration of famotidine was performed. The parameters of gastric residual volume, multiple organ disorder syndrome (MODS) score, acute physiology and chronic health evaluation II (APACHE II) score and PEEP were recorded. Paired t test; Wilcoxon signed ranks test and Univariate analysis with Spearman’s rank correlation were applied to analyse the data.

RESULTS: Statistical significance of longest acid reflux, reflux time of pH<4 and fraction time of acid reflux was observed in ten critically ill patients before and after administration. P value is 0.037, 0.005, 0.005 respectively. Significance change of all bile reflux parameters was observed before and after administration. P value is 0.007, 0.024, 0.005, 0.007, 0.005. GER has positive correlation with APACHE II score and gastric residual volume with correlation coefficient of 0.720, 0.932 respectively.

CONCLUSION: GER and DGER are much improved after the administration of famotidine. GER is correlated with APACHE II score and gastric residual volume.

Xin Y, Dai N, Zhao L, Wang JG, Si JM. The effect of famotidine on gastroesophageal and duodeno-gastro-esophageal refluxes in critically ill patients. World J Gastroenterol 2003; 9(2): 356-358 http://www.wjgnet.com/vol1007-9327/9/356.htm

INTRODUCTION

The incidence of GER and DGER is relatively high in critically ill patients. It was reported that the incidence of DGER was 48% and that of DGER 74%. GER and DGER are important causes of esophageal inflammation, ulcer, upper GI bleeding[1], bronchospasm[2] and aspiration pneumonia[3]. In our study using 24 hours’ acid and bile reflux monitoring, the effect of famotidine on GER and DGER was recorded and the relationship between reflux, gastric residual volume, end expiratory pressure (PEEP), APACHE II and MODS scores were studied.

MATERIALS AND METHODS

General conditions

Clinical data: From June, 2001 to February, 2002 nineteen critically ill patients were enrolled including ten males and nine females with age ranging from thirty to seventy-five. Among them there were eleven cerebral trauma patients, four acute cerebrovascular accident, one intracranial neoplasm and three respiratory failure with lung infection. Criteria for enrollment were: fasting for at least 6 hours, on mechanical ventilator support, no enteral nutrition through nasogastric tube (NGT) before, and serum bilirubin level less than 2.0 mg/dl. Exclusion criteria included active gastroenteral bleeding, esophageal and fundic varices, mechanical ileus, previous thoracic or abdominal radiotherapy, esophageal or gastric surgery, cholecystectomy, previous GERD or gastroenteral dynamic disorders, esophageal or upper small intestinal Crohn’s disease. Also excluded were patients receiving cisapride, erythromycin, atropine, theophylline, metoclopramide and acid suppressants within three days.

Drug and equipments

Famotidine (trade name of Xin Fa Ding, Shanghai Sine pharmaceutical company.), pH monitor of dynamical Digitrapper MK III and Bilitec 2000 all produced by Medtronic Synectics Medical Company (Sweden).

Methods

The level of PEEP, the score of MODS and APACHE II (Knaus, 1985) were recorded on the day of study. The electrode of pH monitor was calibrated in buffers of pH 7.01 and 1.07. The Bilitec 2000 probe was calibrated in calibrating fluid. Then two probes were taped together and inserted into patients’ stomach through nostril. Gastroesophageal junction was determined by pH gradient change. After exclusion of torsion by chest X-ray film the probes were taped to the patients’ faces. During the study all patients were kept supine and received TPN nutritional support. All data was analysed by specific software provided by Medtronic Synectics Medical Company. Pathologic acid reflux was defined as the fraction time of pH less than 4, greater than 4%[4]. The pathologic bile reflux was defined as the fraction time of light absorption value more than 0.14, greater than 4 %[5]. MODS and APACHE II score was reevaluated on the second day. Acid and bile reflux monitoring were repeated after the administration of famotidine of 40 mg iv.q12 h. On the third day nasogastric tube was inserted into the stomach and the gastric residual volume was recorded during the famotidine administration.

Ventilation associated pneumonia (VAP) (refer to informal guide for the diagnosis and treatment of nosocomial pneumonia set by CMA, pulmonary division in 1999) was also observed.

Statistics analysis

All results were expressed as x±s (M). Data were analyzed by
 pair-matching t test, Wilcoxon signed rank test, Spearman’s rank correlation.

RESULTS

Scoring
The ranges of PEEP, APACHE II and MODS were 5 mmHg to 15 mmHg, 10 to 26 points and 8 to 18 points respectively in nineteen critically ill patients. No significant differences were found in PEEP, APACHE II and MODS in ten patients before and after administration of famotidine.

Results of esophageal acid reflux
The parameters of acid reflux in ten patients were showed in Table 1. The incidence of pathological acid reflux before famotidine administration was 80 % (8/10) and 30 % (3/10) after famotidine administration. There were significant differences in longest reflux time, reflux time of pH less than 4 and fraction time of reflux.

Table 1 Acid reflux comparison before and after famotidine administration

|                          | Before administration | After administration | P value |
|--------------------------|-----------------------|----------------------|---------|
| Reflux frequency         | 81.60 ±110.57 (49.50) | 39.50±59.44 (22.00)  | 0.059   |
| Frequency of long reflux (>5 min) | 19.90±13.08 (9.50) | 7.60±9.79 (6.00) | 0.052   |
| Longest reflux time (min) | 34.80±64.12 (12.00) | 9.30±10.20 (7.50) | 0.037   |
| pH<4 reflux time (min)   | 146.80±293.46 (34.50) | 27.10±45.68 (14.00) | 0.005   |
| pH<4 fraction time (%)   | 18.43±19.64 (11.43) | 0.44±0.55 (0.18) | 0.005   |

Results of esophageal bile reflux
The parameters of bile reflux in ten patients were shown in Table 2. The incidence of pathological bile reflux before administration was 60 % (6/10) and 20 % (2/10) after famotidine administration. All the parameters were improved after famotidine administration.

Table 2 Bile reflux comparison before and after famotidine administration

|                          | Before administration | After administration | P value |
|--------------------------|-----------------------|----------------------|---------|
| Reflux frequency         | 37.20±19.00 (34.50) | 14.30±12.04 (11.50) | 0.007   |
| Frequency of long reflux (>5 min) | 13.30±5.93 (13.50) | 5.40±7.88 (2.00) | 0.024   |
| Longest reflux time (min) | 111.20±142.42 (18.00) | 17.90±30.63 (5.50) | 0.005   |
| Absorption>0.14 reflux time (min) | 308.00±413.02 (49.50) | 32.60±49.40 (11.00) | 0.007   |
| Absorption>0.14 fraction time (%) | 26.00±27.33 (15.30) | 0.64±10.39 (0.29) | 0.005   |

Esophageal mixed reflux
The incidence of mixed reflux in ten critical ill patients was 50 % (5/10) before famotidine administration and was 20 % (2/10) after famotidine administration. The total incidence of mixed reflux in nineteen patients was 36.84 % after the administration.

Correlation analysis
Before administration reflux time of pH<4 was positively related to APACHE II score with Pearson correlation coefficient of 0.72 (Figure 1). After administration fraction time of acid reflux and APACHE II score were positively related to gastric residual volume with Pearson correlation coefficient of 0.932 and 0.467 respectively (Figure 2,3).

![Figure 1](image1.png) The relationship between pH<4 reflux time and APACHE II score before famotidine administration.

![Figure 2](image2.png) The relationship between acid reflux fraction time and gastric residual volume after famotidine administration.

![Figure 3](image3.png) The relationship between APACHE II score and gastric residual volume.

Aspiration pneumonia and VAP
In our study no aspiration pneumonia and VAP were found.

DISCUSSION
The medical literatures reported that the incidence of GER and DGER could be 78.1 % [6] and 48 % [7] respectively in critically ill patients. Reasons for high reflux rate maybe due to the following: (1) Basic illnesses: Medical literature reported that acute or chronic cerebral injury could decrease lower esophageal sphincter pressure [8] and delay the gastric emptying [9] when accompanied with increased ICP. (2) Posture: Supine position is a high risk factor for GER and DGER. The incidence of GER increased from 12 % to 50 % when position was changed from semirecumbent to supine [10]. (3) Mechanical ventilation: During ventilation swallowing hyperreflexia, inhibition of peristalsis and visceral hypoperfusion due to PEEP were observed [11]. Similar study had not been reported in China. Researches reported that reflux of duodenal juice in gastroesophageal reflux disease was more common than pH...
studies alone would suggest[22] and the combined reflux of gastric and duodenal juices caused severe esophageal mucosal damage[13]. We combined pH monitor with Biliated 2000[14] to detect acid and bile reflux simultaneously. The pH step-up for electrode positioning was successfully carried out in nineteen critically ill patients[15]. Our study showed before the administration of famotidine the incidence of pathological GER and DGER was 80 %, 60 % respectively which was in accordance with the medical literatures.

After famotidine administration acid and bile reflux were much improved. Famotidine is one of the most common drugs used in ICU. Venous injection of famotidine 40 mg twice per day would keep esophagus pH above 4 for twenty hours in our study. Parkman[16] found increased antral phase III migrating motor complexes (MMCs) after administration of ranitidine, famotidine and omeprazole and especially in famotidine. Bortotolli noted the same finding[17,18]. MMC III had the role of “street sweeper” in GI tract. Because of its powerful propulsion which can clean the duodenal contents reflux to stomach in the end of MMC II, MMC may have an anti-reflux role[19]. Before MMC III there is a short duration of reversed peristalsis[20] when MMC III is evoked by bile and pancreatic juice excretion and neutralization of acid in the duodenum.[21] MMC III could be inhibited by continuous injection of acid in the duodenum. In conclusion famotidine improved GER through increasing gastric pH and improved DGER through increasing MMC III due to increased duodenal pH. Decreased gastric residual volume after acid inhibition may be one of the mechanisms.

In our study we also found that reflux time of pH<4 was positively correlated to APACHE II score (Figure 1). This suggests that GER and DGER occur more commonly when critical illness occurs and normal defense mechanisms are disturbed. It was reported that as part of scoring APACHE II Glasgow score was closely related to delayed gastric emptying[22], which was consistent with our findings (Figure 3). We also found that gastric residual volume was positively related to fraction time of acid reflux (Figure 2). This may explain why famotidine may improve GER indirectly. Nasogastric tube, H₂ blocker[23], sedatives[24,25], muscle relaxant[26] are known factors for ventilation associated pneumonia. But in our study there was no aspiration pneumonia or VAP. So famotidine may not increase the incidence of pneumonia. Furthermore by decreasing GER and DGER it may lessen the opportunity for aspiration. There is a need for further study in larger groups of patients to define more clearly this relationship.

REFERENCES

1. Niederau C, Lubke H, Schumacher B, Strohmeyer G. Endoscopy in the intensive care unit. Z. Gastroenterol. 1994; 32: 465-469
2. Tomonaga T, Awad ZT, Filipi CJ, Hinder RA, Selima M, Tercero J Jr, Marsh RE, Shiino Y, Welch R. Symptom predictability of reflux-induced respiratory disease. Dig Dis Sci 2002; 47: 9-14
3. Saxe JM, Ledgerwood AM, Lucas CE, Lucas WF. Lower esophageal sphincter dysfunction precludes safe gastric feeding after head injury. J Trauma 1994; 37: 581-584
4. Richter JE, Bradley LA, DeMeester TR, Wu WC. Normal 24-hr ambulatory esophageal pH values. Influence of study center, pH electrode, age and gender. Dig Dis Sci 1992; 37: 849-856
5. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-1199
6. Gustafsson PM, Tibbling L. Gastro-oesophageal reflux and oesophageal dysfunction in children and adolescents with brain damage. Acta Paediatr 1994; 83: 1081-1085
7. Wilmer A, Tack J, Frans E, Dils H, Vanderschueren S, Gneime A, Bobbaers H. Duodenogastroesophageal reflux and esophageal mucosal injury in mechanically ventilated patients. Gastroenterology 1999; 116: 1293-1299
8. Vane DW, Shiffler M, Grosfeld JL, Hall P, Angelides A, Weber TR, Fitzgerald JF. Reduced lower esophageal sphincter (LES) pressure after acute and chronic brain injury. J Fisiatr Surg 1962; 17: 990-994
9. Kao CH, ChangLai SP, Chieng PU, Yen TC. Gastric emptying in head-injured patients. Am J Gastroenterol 1998; 93: 1108-1112
10. Ibanez J, Penafiel A, Aurrich JM, Marse P, Jordà R, Mata F. Gastroesophageal reflux in intubated patients receiving enteral nutrition: effect of supine and semirecumbent position. J Parater Nutr 1992; 16: 419-422
11. Dive A, Moulard M, Jonard P, Jamart J, Maliuev P. Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study. Crit Care Med 1994; 22: 441-447
12. Dai F, Gong J, Zhang R, Luo JY, Wang XQ. Assessment of duodenogastroesophageal reflux by combined continuous intragastric pH and bilirubin monitoring. World J Gastroenterol 2002; 8: 382-384
13. Kauer WKH, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is much more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995; 222: 525-533
14. Bortolotti M, Bucciani F, Baldini F, Così F, Falciai R, Mazzanti R, Castagnoli A, Passeri A, Boscherini S. Long-term ambulatory endoscopy reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993; 38: 1297-1306
15. Klauser AG, Schindlbek NE, Muller-Lissner SA. Esophageal 24-h pH monitoring: Is prior manometry necessary for correct positioning of the electrode? Am J Gastroenterol 1990; 85: 1463-1467
16. Parkman HP, Urbain J-L, Knight LC, Brown KL, T rate DM, Miller MA, Maurer A.H., Fisher RS. Effect of gastric acid suppressants on human gastric motility. Gut 1996; 42: 243-250
17. Bortolotlli M, Cuccia C, Sarti P, Brunelli F, Del Campo L, Barbara L. Interdigestive gastroesophageal reflux in critically ill patients with ulcer-like dyspepsia: effect of ranitidine. H. Pylor gastrectomology 1992; 39: 31-33
18. Bortolotti M, Pinotti R, Sarti P, Barbara L. Esophageal electromyography in scleroderma patients with functional dysphagia. Am J Gastroenterol 1989; 84: 1497-1502
19. Keane FB, Dimagno EP, Malageleda JR. Duodenogastroesophageal reflux in humans: its relationship to fasting antroduodenal motility and gastric, pancreatic, and biliary secretion. Am J Gastroenterol 1992; 87: 726-731
20. Dalenback J, Abrahamson H, Bjorson E, Fandriks L, Mattsson A, Olbe L, Svennerholm A, Sjovall H. Human duodenogastroesophageal reflux, retroperistalsis, and MMC. Am J Physiol 1998; 275: R762-769
21. Woodti W, Owyang C. Duodenal pH governs interdigestive motility in humans. Am J Physiol 1995; 268: G146-152
22. Acosta Escribano J, Carrasco Moreno R, Fernandez Vivias M, Navarro Polo JN, Mas Serrano P, Sanchez Paya J, Caturia Such IJ. Gastric intolerance and hypertension intracranial pressure and their association with severity indexes in patients with severe head injury. Nutr Hosp 2003; 16: 262-267
23. Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Bunting LM, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275: 308-314
24. Georges H, Leroy O, Guery B, Alfantari S, Beaucarie G. Predicting factors for nosocomial pneumonia in patients receiving mechanical ventilation and requiring tracheostomy. Chest 2000; 118: 767-774
25. Kolbel CB, Rippel K, Klar H, Singer MV, van Aders K, Fiedler F. Esophageal motility disorders in critically ill patients: a 24-hour manometric study. Intensive Care Med 2000; 26: 1421-1427
26. Schindler MB, Bohn DJ, Bryan AC. The effect of single-dose and continuous skeletal muscle paralysis on respiratory system compliance in paediatric intensive care patients. Intensive Care Med 1996; 22: 496-491

Edited by Xu JY